1935196-58-9Relevant academic research and scientific papers
Pyrazolo six-membered nitrogen heterocyclic compound as well as synthesis method and application thereof
-
Paragraph 0161-0165, (2022/03/27)
The invention provides a pyrazolo six-membered nitrogen heterocyclic compound which is a compound as shown in a structural general formula I or a pharmaceutically acceptable salt of the compound as shown in the structural general formula I. In the pyrazolo six-membered nitrogen heterocyclic compound, groups X1, X2 and X3 are independently selected from carbon atoms or nitrogen atoms respectively, and at least one of the groups X1, X2 and X3 is a nitrogen atom; the group R1 is a substituted aryl group, a substituted aromatic heterocyclic group, a sulfo-aryl group or a sulfo-heterocyclic group; and the group R2 is a nitrogen heterocyclic group. The invention also provides a preparation method and application of the pyrazolo six-membered nitrogen heterocyclic compound. Tests show that the pyrazolo six-membered nitrogen heterocyclic compound has an effect of inhibiting SHP2, so that a new way is opened up for finding a novel-structure and efficient anti-cancer drug based on an SHP2 target.
SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
-
, (2021/04/02)
The disclosure is in part directed to crystalline forms of (R)-1′-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4′-piperidin]-3-amine, its salt, and variants thereof.
SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11
-
Paragraph 0363, (2019/11/19)
The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their applica
SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
-
, (2019/10/15)
The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS
-
, (2018/05/24)
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 0234, (2018/04/20)
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.
